Dotinurad—Exploring Its Potential and Applications in Modern Medicine II

Advantages of Dotinurad

High Selectivity for URAT1

Dotinurad is a highly selective inhibitor of the urate transporter protein 1 (URAT1). By effectively inhibiting URAT1 in the renal proximal tubules, it promotes uric acid excretion and reduces serum uric acid levels. Unlike non-selective URAT1 inhibitors, Dotinurad does not affect the function of ABCG2 and OAT1/3, resulting in higher efficiency in lowering serum uric acid levels.

High Efficacy

Compared to non-selective URAT1 inhibitors, Dotinurad achieves a more significant reduction in serum uric acid levels within the same treatment period. In a Phase III clinical study conducted in China, the 4 mg dose of Dotinurad achieved a 73.6% response rate at 24 weeks, significantly higher than the 38.1% response rate for febuxostat 40 mg, demonstrating Dotinurad's superior efficacy.

Safety

Dotinurad's metabolites do not contain "p-benzoquinone" or similar structures, avoiding the hepatotoxicity associated with benzbromarone. Long-term use has shown no significant impact on renal or liver function, indicating a favorable safety profile.

Good Tolerability

Clinical studies have shown that Dotinurad is well-tolerated. The incidence of treatment-emergent adverse events (TEAEs) was similar to that of febuxostat, with a low incidence of severe or serious adverse events. No serious adverse events (SAEs) related to Dotinurad were reported.

Reduced Risk of CKD and CVD

By not inhibiting ABCG2 and OAT1/3, Dotinurad does not increase toxin levels in the blood and helps reduce intrarenal uric acid accumulation, potentially lowering the risk of chronic kidney disease (CKD) and cardiovascular disease (CVD).

Patent Invalidation

The crystal form patent for Dotinurad (CN201880027057.7) has been declared entirely invalid by the China National Intellectual Property Administration. This is the first successful invalidation challenge against the patent, filed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Although the crystal form patent has been invalidated, Dotinurad's core compound patent remains valid and has not been challenged. The compound patent is expected to expire on September 29, 2030.

In conclusion, Dotinurad represents a significant advancement in the treatment of Hyperuricemia and gout, offering high efficacy, safety, and tolerability. Its potential in addressing the growing global burden of these conditions positions it as a key player in the future of gout management.